MedPath

Mechanisms of albuminuria in diabetes: reversal of injury to the glycocalyx by the ace-inhibitor lisinopril

Conditions
Diabetes Mellitus, microalbuminuria, glycocalyx, ACE-inhibitor
Registration Number
NL-OMON23821
Lead Sponsor
Academic Medical Center (AMC), Department of Internal Medicine
Brief Summary

/A

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Not specified
Target Recruitment
20
Inclusion Criteria

1. Caucasian males

2. Diagnosis of type 1 diabetes according to ADA criteria

Exclusion Criteria

1. Hypertension as defined by systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg or use of antihypertensive drugs

2. Previous use of RAS inhibitor2

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The primary outcome of this study is the change in microvascular glycocalyx thickness after treatment.
Secondary Outcome Measures
NameTimeMethod
Secondary outcomes are changes in oxidative stress, inflammation, coagulation microalbuminuria and glomerular charge selectivity.
© Copyright 2025. All Rights Reserved by MedPath